Tradestie Institutional Equity Comparison Engine
ABTS vs ATHA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ATHA Overall Edge
ATHA Captures Institutional Edge (2โ0 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Athira Pharma, Inc. Common Stock (ATHA) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, ABTS trades at N/M Forward P/E with -46.3% operating margin (-20.0% YoY revenue) versus ATHA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ABTS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ATHA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ABTS N/M vs ATHA N/M Fwd P/E
Growth & Margin Winner
ATHA
Op Margin -46.3% vs 0.0% ยท YoY -20.0% vs +0.0%
Momentum & Technical Winner
ATHA
1Y -95.1% vs +12.5% ยท 52W Pos 0% vs 80%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ABTS
NASDAQ
Abits Group Inc Ordinary Shares
Finance Services
$0.31
-6.33% 1D
Market Cap
$1.1M
1M Return
-73.64%
1Y Return
-95.1%
Forward P/E
N/M
Unified AI Score
50.5 / 100
HOLD
Tech 50.0
Fund 55.0
Flow 50.0
Mom 59.0
ATHA
NASDAQ
Athira Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.75
-6.12% 1D
Market Cap
$26.6M
1M Return
+73.75%
1Y Return
+12.5%
Forward P/E
N/M
Unified AI Score
56.2 / 100
HOLD
Tech 55.0
Fund 52.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ABTS -95.1%
ATHA +12.5%
Spread: +52.44 pp (ATHA Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ABTS TTM Op. Margin: -46.3%
ATHA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABTS vs ATHA. Trailing 12-month operating profitability (ABTS -46.3% vs ATHA 0.0%) and valuation multiples (ABTS N/M vs ATHA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ABTS | ATHA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.1M | $26.6M | Larger Scale | ATHA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -20.0% | +0.0% | Higher Growth | ATHA |
| Operating Margin (TTM) Profitability | -46.3% | 0.0% | Higher Margin | ATHA |
| Net Profit Margin Profitability | -60.8% | 0.0% | Higher Margin | ATHA |
| Return on Equity (ROE) Capital Efficiency | -60.0% | -89.4% | Higher ROE | ABTS |
| 52-Week Range Position Momentum | 0% ($0โ$7) | 80% ($0โ$8) | Stronger Trend | ATHA |
| Beta / 30D Volatility Risk Regime | 1.70ฮฒ ยท 224% Vol | 6.17ฮฒ ยท 241% Vol | Lower Realized Risk | ABTS |
| Unified Institutional Score Composite Signal | 50.5 / 100 (HOLD) | 56.2 / 100 (HOLD) | Higher Composite | ATHA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ABTS vs ATHA Buy Guide
ABTS
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ATHA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ABTS nor ATHA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.